Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 21, 2017
Pharmacy Choice - News - Pharmaceutical Development - November 21, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/21/17 - AB Science announces the publication of Preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments
Paris, 21 November 2017, 5.45 pm Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine Phase 3 clinical studies on-going for masitinib-gemcitabine combination in pancreatic cancer, refractory peripheral T-cell lymphoma and refractory ovarian...
11/21/17 - ACADIA Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference on November 28, 2017
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 10:00 a.m. Eastern Time
11/21/17 - Aclaris Therapeutics Presents New Data at American College of Rheumatology Annual Meeting For ATI-450, a MK2 pathway Inhibitor
Aclaris Therapeutics, Inc., a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that Dr. Gabriel Mbalaviele presented data from pre-clinical studies of Aclaris...
11/21/17 - Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib in Patients with IDH1 Mutant Positive Glioma
SAN FRANCISCO- Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented updated data from the dose expansion cohort of the Phase 1 study evaluating single agent ivosidenib in patients with progressive low grade isocitrate dehydrogenase-1 mutant glioma. The data were present
11/21/17 - AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30 a.m.
AIT Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that management will hold a clinical update meeting on November 28, 2017 at 7:30 a.m. to discuss data from its NO-NTM Phase 2 clinical t
11/21/17 - Ampio Announces Start of Open Label Extension Study to Support Commercial Label of Repeat Administration of Ampion in Severe Osteoarthritis of the Knee
ENGLEWOOD, Colo.- Ampio Pharmaceuticals, Inc. announced the beginning of an Open Label Extension study of Ampion in patients with severe osteoarthritis of the knee. The OLE study offers patients an opportunity to receive repeat injections of Ampion after they have completed the pivotal clinical trial. This OLE study will address the regulatory requ
11/21/17 - ARCA biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases
WESTMINSTER, Colo.- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office's issuance of a patent on methods of treating cardiovascular disease and conditions with a thiol-substituted isosorbide...
11/21/17 - ARDELYX, INC. FILES (8-K) Disclosing Other Events
On November 21, 2017, Ardelyx, Inc. provided an update on the development of its cardiorenal pipeline with a focus on tenanpanor and next-generation opportunities. Following learnings from the Company's first completed Phase 3 study of tenapanor for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis, the Company soug
11/21/17 - Best in Class Pharma Market Research Reports: DelveInsight has a database of 3000+ Reports across 750+ Indications.
New Delhi, India 11/20/2017 About DelveInsight. DelveInsight is a leading Market Research and Business Consulting firm focused exclusively on life sciences. It supports companies by providing end to end comprehensive solutions to improve their performance and in making long-lasting decision for their businesses.
11/21/17 - Binding molecule could improve injected radiation therapy [Tehran Times (Iran)]
Four years ago, radium-223 dichloride was the first therapeutic alpha-emitting radionuclide to be approved by the Food and Drug Administration for clinical use in cancer patients. A Cornell team led by Justin Wilson, assistant professor in the Department of Chemistry and Chemical Biology in the College of Arts and Sciences, and John Babich, profess
11/21/17 - Biocon shares rise 7% after Bengaluru unit gets US FDA clearance [Arab Times (Kuwait)]
Biocon Ltds shares jumped over 7% after the company said on Monday that its manufacturing facility in Bengaluru, which had received observations relating to lapses in quality compliance earlier this year, has been cleared by the US Food and Drug Administration. The US FDA has issued an Establishment Inspection Report in relation to the cGMP inspect
11/21/17 - BioLineRx Reports Third Quarter 2017 Financial Results
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the third quarter ended September 30, 2017. Initiation of two additional Phase 1 b/2 studies under collaboration with Genentech, following the first study which was initiated in July 2017. All studies are explorin
11/21/17 - Building on Cures Act, FDA lays out cell therapy fast track in regenerative medicine framework [Arab News (Saudi Arabia)]
The FDA has created a policy framework for cellular therapies and other regenerative medicines by releasing two draft and two final guidance documents. In the guidance, the FDA takes the RMAT status created by the 21st Century Cures Act, contextualizes it against other regulatory designations and explains how and why companies may want to apply.
11/21/17 - Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma
PETACH TIKVA, Israel- Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that its previously majority owned subsidiary OphthaliX, Inc. has successfully completed a merger with Wize Pharma Ltd.. As a result of the merger, Can-
11/21/17 - Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
Cancer Prevention Pharmaceuticals, a clinical stage biotechnology company, today announced it will give a corporate presentation at the Piper Jaffray 29 th Annual Healthcare Conference on November 28, 7:50 -8: 10 a.m. ET at the Lotte New York Palace in New York City. In 2016 CPP signed a collaboration agreement with Sucampo Pharmaceuticals, Inc. th
11/21/17 - Catabasis Pharmaceuticalsto Present at 29th Annual Piper Jaffray Healthcare Conference
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present an overview of the company in a fireside chat at the 29 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at 2:00pm ET at the Lotte New York Palace in New York, NY.
11/21/17 - Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse in Ambulatory Patients with Spinal Muscular Atrophy (SMA)
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the initiation of a company-sponsored, adequate and well-controlled, proof-of-concept clinical trial evaluating safety,...
11/21/17 - CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Financial Statements and Exhibits
CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Financial Statements and ExhibitsItem 9.01 Financial Statements and Exhibits. 99.1 Press release issued by the Company on November21, 2017. 2 CATALYST PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d485575dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalyst Pharmaceuticals Announces Phase 2 Study of
11/21/17 - Celsion Announces Publication of the Study of ThermoDox + Ultrasound, TARDOX Study Protocol in the Journal of Therapeutic Ultrasound [Syrian Arab News Agency]
-Celsion Corporation today announced publication of the manuscript, "Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin using focused ultrasound in patients with liver tumours," in the Journal of Therapeutic Ultrasound 2017 5:28. The TARDOX Study, whic
11/21/17 - Chugai's HEMLIBRA Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors
The US Biologics License Application was submitted by Genentech, a member of Roche Group. 'We are pleased that HEMLIBRA, a biopharmaceutical created by Chugai scientists based on their exceptional idea, has received its first regulatory approval,' said Chugai's President& COO, Tatsuro Kosaka.' HEMLIBRA is a first in class biopharmaceutical which is
11/21/17 - Cipla Receives Final Approval for Generic Pulmicort Respules
India, Mumbai- Cipla Ltd, a global pharmaceutical company, today announced that it has received final approval for its Abbreviated New Drug Application for Budesonide Inhalation Suspension, 0.25 mg/2mL, 0.5 mg/2mL, and 1 mg/2mL from the United States Food and Drug Administration to market a generic version of Astrazeneca's Pulmicort Respules.
11/21/17 - Critical Outcome Announces Pharmacokinetic Data from Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
London, Ontario and Boston, MA- Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced pharmacokinetic data from the dose-escalation portion of its Phase 1 trial of COTI-2 in gynecological malignancies that support the continued developme
11/21/17 - Cytokinetics Announces Negative Results From VITALITY-ALS
Cytokinetics, Incorporated today announced that VITALITY-ALS, the international Phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis, did not meet the primary endpoint of change from baseline in slow vital capacity which was evaluated at 24 weeks following randomization or any of the secondary endpoints in the trial
11/21/17 - Cytokinetics, Incorporated (NASDAQ:CYTK) Files An 8-K Other Events
Cytokinetics, Incorporated (NASDAQ:CYTK) Files An 8-K Other EventsItem 8.01. Other Events. CYTOKINETICS INC ExhibitEX-99.1 2 exh-991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Cytokinetics Announces Negative Results From VITALITY-ALS Phase 3 Clinical Trial of Tirasemtiv in Patients with ALS Did Not Meet Primary or Secondary Endpoints Results to be Pr
11/21/17 - Data from Phase III ALCYONE Study of Daratumumab Accepted for Oral Presentation at Annual Meeting of the American Society of Hematology
Copenhagen, Denmark; November 21, 2017 Genmab A/S announced today that data from the Phase III ALCYONE study of daratumumab in combination with bortezomib, melphalan and prednisone versus VMP alone treating newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation, which was submitted by our collaborat
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement